コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ecommend an intranasal corticosteroid over a leukotriene receptor antagonist.
2 d be blocked using a pharmacologic cysteinyl-leukotriene receptor antagonist.
3 leukotriene B4 receptor but not a cysteinyl-leukotriene receptor antagonist.
4 mple, H1- and H2-antihistamines or cysteinyl leukotriene receptor antagonists.
5 ticosteroids, long-acting beta-agonists, and leukotriene receptor antagonists.
6 successfully identified clinically effective leukotriene receptor antagonists.
7 roids (21.5%; 95% CI: 20.7%-22.3%; p<0.001), leukotriene receptor antagonists (13.4%; 95% CI: 12.9%-1
8 long-acting beta agonists, theophyllines, or leukotriene-receptor antagonists, adjusted stepwise acco
9 ge in FEV1 in the Characterizing Response to Leukotriene Receptor Antagonist and Inhaled Corticostero
11 osteroids [topical (swallowed) or systemic], leukotriene receptor antagonists and, most recently, bio
12 daily inhaled corticosteroids (ICSs), daily leukotriene receptor antagonists, and as-needed ICS trea
13 include daily inhaled corticosteroids, daily leukotriene receptor antagonists, and combination therap
17 We aimed to assess whether montelukast, a leukotriene receptor antagonist, can improve symptoms or
18 fluticasone twice daily plus 5 or 10 mg of a leukotriene-receptor antagonist daily (LTRA step-up).
21 agents such as cromolyn and the new class of leukotriene receptor antagonists have demonstrated benef
22 ukotriene synthesis inhibitors and cysteinyl leukotriene receptor antagonists have shown efficacy in
23 ay disease include the use of muscarinic and leukotriene receptor antagonists; however, these pharmac
24 ium Respimat added to ICSs with or without a leukotriene receptor antagonist in a phase III trial in
25 nical efficacy of inhaled glucocorticoids to leukotriene receptor antagonists in children with mild t
26 vide benefit if combined with montelukast, a leukotriene receptor antagonist, in patients whose sympt
27 he effectiveness of montelukast, a cysteinyl leukotriene receptor antagonist, in the treatment of pos
28 s, long-acting inhaled beta2-stimulants, and leukotriene receptor antagonists, increased year after y
30 emists in the design of potent and selective leukotriene receptor antagonists-leukotriene structural
31 to ICS background therapy, with or without a leukotriene receptor antagonist; long-acting beta2-agoni
32 steroid (ICS step-up therapy) or addition of leukotriene receptor antagonist (LTRA step-up therapy) o
34 ment with ICSs alone (n = 1758) or ICSs plus leukotriene receptor antagonist (LTRAs; n = 354) or ICSs
38 hieved by LABAs (improved lung function) and leukotriene receptor antagonists (LTRAs; protection agai
40 yclo-oxygenase inhibitor indomethacin or the leukotriene receptor antagonist MK-571, indicating that
41 o examine a potential protective role of the leukotriene receptor antagonist montelukast on future ri
43 for a daily inhaled corticosteroid, a daily leukotriene receptor antagonist, or a mast cell stabiliz
47 ected animals with MC-stabilizing drugs or a leukotriene receptor antagonist restores vascular integr
48 useful add-on therapies for AR include oral leukotriene receptor antagonists, short bursts of a nasa
52 We evaluated the ability of montelukast, a leukotriene-receptor antagonist, to protect such patient
53 nist, long-acting muscarinic antagonist, and leukotriene receptor antagonist was hospitalized with a
54 choconstriction by a single oral dose of the leukotriene receptor antagonist zafirlukast was assessed
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。